- Home
- GGZ vs STTK Comparison
GGZ vs STTK Comparison
Compare GGZ & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGZ
- STTK
- Stock Information
- Founded
- GGZ 2013
- STTK 2016
- Country
- GGZ United States
- STTK United States
- Employees
- GGZ N/A
- STTK N/A
- Industry
- GGZ Investment Managers
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- GGZ Finance
- STTK Health Care
- Exchange
- GGZ Nasdaq
- STTK Nasdaq
- Market Cap
- GGZ 114.8M
- STTK 112.6M
- IPO Year
- GGZ N/A
- STTK 2020
- Fundamental
- Price
- GGZ $14.45
- STTK $2.45
- Analyst Decision
- GGZ
- STTK Hold
- Analyst Count
- GGZ 0
- STTK 6
- Target Price
- GGZ N/A
- STTK $2.67
- AVG Volume (30 Days)
- GGZ 12.8K
- STTK 411.6K
- Earning Date
- GGZ 01-01-0001
- STTK 11-13-2025
- Dividend Yield
- GGZ 5.39%
- STTK N/A
- EPS Growth
- GGZ N/A
- STTK N/A
- EPS
- GGZ 1.75
- STTK N/A
- Revenue
- GGZ N/A
- STTK $2,997,000.00
- Revenue This Year
- GGZ N/A
- STTK N/A
- Revenue Next Year
- GGZ N/A
- STTK N/A
- P/E Ratio
- GGZ $6.79
- STTK N/A
- Revenue Growth
- GGZ N/A
- STTK N/A
- 52 Week Low
- GGZ $9.43
- STTK $0.69
- 52 Week High
- GGZ $12.50
- STTK $2.71
- Technical
- Relative Strength Index (RSI)
- GGZ 50.23
- STTK 68.63
- Support Level
- GGZ $14.35
- STTK $2.29
- Resistance Level
- GGZ $14.77
- STTK $2.71
- Average True Range (ATR)
- GGZ 0.18
- STTK 0.19
- MACD
- GGZ -0.04
- STTK -0.01
- Stochastic Oscillator
- GGZ 13.40
- STTK 72.17
About GGZ Gabelli Global Small and Mid Cap Value Trust (The) of Beneficial Interest
The Gabelli Global Small and Mid Cap Value Trust is a diversified closed-ended management investment company whose investment objective is long-term capital growth. It invests in equity securities such as common stock and preferred stock of companies.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.